IRCT20191228045924N2招募中4 期
Application of Methylene Blue Along with Complementary Materials for Treatment of COVID-19 Outpatients with Less Than 8 Days from First Day of Clinical Symptoms
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Outpatient COVID-19 patients who confirmed by PCR or HRCT referred to pulmonary clinic
- •SPO2 is between 70-96 after taking off the mask
排除标准
- •Severe impairment of liver and heart
- •Renal insufficiency including severe renal impairment
- •G6PD enzyme deficiency
研究者
相似试验
招募中
3 期
Methylene Blue as a Vasoplegic Syndrome preventive agent in cardiac surgeriesPostoperative vasoplegic syndromeH02.403.810.803RBR-96ch27cHospital das clínicas da Faculdade de Medicina da Universidade de São Paulo
尚未招募
3 期
Study of injection methylene blue after surgery around anus for decreasing paiCTRI/2023/09/057852Dr Pratik Jadhav
尚未招募
3 期
Comparison of two different medicines named Methylene Blue and Vasopressin for increasing blood pressure in patients with infection and low blood pressureCTRI/2023/06/053979AIIMS New Delhi
进行中（未招募）
1 期
The safety and effectiveness of Methylene Blue MMX® tablets given to patients undergoing screening or surveillance colonoscopy.EUCTR2012-003983-32-DECosmo Technologies Ltd1,270
进行中（未招募）
1 期
The safety and effectiveness of Methylene Blue MMX® tablets given to patients undergoing screening or surveillance colonoscopy.EUCTR2012-003983-32-LTCosmo Technologies Ltd1,270